Lorenz C Hofbauer

List of Publications by Year
in descending order

361	25,848	9786 73	8167 148
papers	citations	h-index	g-index

399	399	399	23654
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Osteoporosis: now and the future. Lancet, The, 2011, 377, 1276-1287.	13.7	1,973
2	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2016, 375, 1532-1543.	27.0	1,099
3	The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption. Journal of Bone and Mineral Research, 2000, 15, 2-12.	2.8	1,031
4	Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases. JAMA - Journal of the American Medical Association, 2004, 292, 490.	7.4	824
5	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. Endocrinology, 1999, 140, 4382-4389.	2.8	690
6	Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes and Endocrinology,the, 2017, 5, 898-907.	11.4	615
7	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells*. Endocrinology, 1999, 140, 4367-4370.	2.8	589
8	Interleukin-1Î² and tumor necrosis factor-Î±, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 1999, 25, 255-259.	2.9	575
9	Role of receptor activator of nuclear factor-ÎºB ligand and osteoprotegerin in bone cell biology. Journal of Molecular Medicine, 2001, 79, 243-253.	3.9	492
10	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. Journal of Bone and Mineral Research, 2009, 24, 153-161.	2.8	486
11	Postmenopausal osteoporosis. Nature Reviews Disease Primers, 2016, 2, 16069.	30.5	462
12	Osteoporosis in Patients With Diabetes Mellitus. Journal of Bone and Mineral Research, 2007, 22, 1317-1328.	2.8	406
13	The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nature Immunology, 2012, 13, 465-473.	14.5	369
14	RANK Ligand and Osteoprotegerin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 549-553.	2.4	356
15	Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1024-1028.	3.6	299
16	Bone, sweet boneâ€"osteoporotic fractures in diabetes mellitus. Nature Reviews Endocrinology, 2012, 8, 297-305.	9.6	295
17	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International, 2012, 23, 2257-2276.	3.1	291
18	Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines. Biochemical and Biophysical Research Communications, 1998, 250, 776-781.	2.1	283

#	Article	IF	Citations
19	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry, 2011, 57, 411-420.	3.2	282
20	Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human Osteoblasts. Biochemical and Biophysical Research Communications, 2002, 291, 680-686.	2.1	270
21	Leptin Reduces Ovariectomy-Induced Bone Loss in Rats. Endocrinology, 2001, 142, 3546-3553.	2.8	267
22	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.. Endocrinology, 2000, 141, 4768-4776.	2.8	255
23	RANK ligand and osteoprotegerin in myeloma bone disease. Blood, 2003, 101, 2094-2098.	1.4	231
24	Vascular calcification and osteoporosisâ€"from clinical observation towards molecular understanding. Osteoporosis International, 2007, 18, 251-259.	3.1	204
25	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology, 1999, 140, 4382-4389.	2.8	204
26	Effects of Immunosuppressants on Receptor Activator of NF-Î²B Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 2001, 280, 334-339.	2.1	196
27	Chiral spin liquid and emergent anyons in a Kagome lattice Mott insulator. Nature Communications, 2014, 5, 5137.	12.8	189
28	Localization of Osteoprotegerin, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, and Receptor Activator of Nuclear Factor-Î²B Ligand in Mol^nckebergâ€™s Sclerosis and Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4104-4112.	3.6	185
29	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1855.	7.4	180
30	Receptor activator of nuclear factor-Î²B ligand and osteoprotegerin. Cancer, 2001, 92, 460-470.	4.1	166
31	miR-125b Regulates Calcification of Vascular Smooth Muscle Cells. American Journal of Pathology, 2011, 179, 1594-1600.	3.8	166
32	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells. Endocrinology, 1999, 140, 4367-4370.	2.8	164
33	Regenerative potential of glycosaminoglycans for skin and bone. Journal of Molecular Medicine, 2012, 90, 625-635.	3.9	161
34	Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3162-3165.	3.6	161
35	Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nature Communications, 2014, 5, 5215.	12.8	160
36	The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrology Dialysis Transplantation, 2008, 23, 3263-3271.	0.7	154

#	Article	IF	Citations
37	The Role of Receptor Activator of Nuclear Factor-Î¹B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2355-2363.	3.6	150
38	Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. Scientific Reports, 2017, 7, 6460.	3.3	150
39	NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. Journal of Clinical Investigation, 2013, 123, 4731-4738.	8.2	142
40	Inhibition of Receptor Activator of NF-Î¹B Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice. American Journal of Pathology, 2009, 175, 473-478.	3.8	138
41	Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone, 2014, 58, 48-54.	2.9	133
42	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. Diabetes, 2016, 65, 1757-1766.	0.6	132
43	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	3.6	132
44	Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clinical Cancer Research, 2003, 9, 1436-40.	7.0	124
45	Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E1220-E1228.	3.5	123
46	Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 207-220.	11.4	123
47	Prevention of glucocorticoidâ€induced bone loss in mice by inhibition of RANKL. Arthritis and Rheumatism, 2009, 60, 1427-1437.	6.7	121
48	Exploring the biology of vascular calcification in chronic kidney disease: What's circulating?. Kidney International, 2008, 73, 384-390.	5.2	120
49	The Role of Receptor Activator of Nuclear Factor-ÂB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2355-2363.	3.6	118
50	Androgen effects on bone metabolism: recent progress and controversies. European Journal of Endocrinology, 1999, 140, 271-286.	3.7	117
51	Osteoprotegerin: a link between osteoporosis and arterial calcification?. Lancet, The, 2001, 358, 257-259.	13.7	112
52	Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. European Journal of Endocrinology, 1999, 141, 195-210.	3.7	106
53	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes and Endocrinology,the, 2014, 2, 830-842.	11.4	106
54	Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. Journal of Bone and Mineral Research, 2013, 28, 627-638.	2.8	105

#	Article	IF	Citations
55	WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. Journal of Bone and Mineral Research, 2012, 27, 575-585.	2.8	100
56	Novel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease. Calcified Tissue International, 2003, 74, 103-106.	3.1	98
57	Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood, 2004, 103, 3480-3489.	1.4	96
58	Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia, 2009, 52, 2478-2488.	6.3	96
59	Gorham-Stout Disease-Stabilization During Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2004, 20, 350-353.	2.8	95
60	Endocrine aspects of bone metastases. Lancet Diabetes and Endocrinology,the, 2014, 2, 500-512.	11.4	95
61	Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. Journal of Cellular Biochemistry, 2002, 84, 725-735.	2.6	93
62	Raloxifene Concurrently Stimulates Osteoprotegerin and Inhibits Interleukin-6 Production by Human Trabecular Osteoblasts. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4206-4213.	3.6	91
63	Novel approaches to target the microenvironment of bone metastasis. Nature Reviews Clinical Oncology, 2021, 18, 488-505.	27.6	91
64	Leptin Reduces Ovariectomy-Induced Bone Loss in Rats. Endocrinology, 2001, 142, 3546-3553.	2.8	91
65	The role of osteoprotegerin and receptor activator of nuclear factor ?B ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis and Rheumatism, 2001, 44, 253-259.	6.7	89
66	Osteoprotegerin Gene Polymorphisms in Men with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3764-3768.	3.6	88
67	Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188351.	7.4	87
68	Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen.. Journal of Clinical Investigation, 1998, 101, 413-422.	8.2	86
69	Coagulation disorders in thyroid diseases. European Journal of Endocrinology, 1997, 136, 1-7.	3.7	85
70	Bone health during endocrine therapy for cancer. Lancet Diabetes and Endocrinology,the, 2018, 6, 901-910.	11.4	85
71	Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties. Endocrine Connections, 2019, 8, R55-R70.	1.9	81
72	Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line. Endocrinology, 1999, 140, 5579-5586.	2.8	80

#	Article	IF	Citations
73	Approach to the patient with secondary osteoporosis. European Journal of Endocrinology, 2010, 162, 1009-1020.	3.7	80
74	Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells. Molecular Endocrinology, 2009, 23, 1525-1531.	3.7	79
75	Selective glucocorticoid receptor modulation maintains bone mineral density in mice. Journal of Bone and Mineral Research, 2012, 27, 2242-2250.	2.8	79
76	Thy-1 (CD90) promotes bone formation and protects against obesity. Science Translational Medicine, 2018, 10, .	12.4	76
77	Serum Level of the Phosphaturic Factor FGF23 Is Associated with Abdominal Aortic Calcification in Men: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E575-E583.	3.6	75
78	The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. Biomaterials, 2012, 33, 8418-8429.	11.4	73
79	The Role of Osteoclast-Associated Receptor in Osteoimmunology. Journal of Immunology, 2011, 186, 13-18.	0.8	71
80	Pheochromocytoma â€“ update on disease management. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 11-26.	3.2	70
81	Myelodysplasia is in the niche: novel concepts and emerging therapies. Leukemia, 2015, 29, 259-268.	7.2	70
82	Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporosis International, 2006, 17, 693-703.	3.1	69
83	An antiâ€inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB Journal, 2011, 25, 1323-1332.	0.5	69
84	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology, 2000, 141, 4768-4776.	2.8	68
85	Regulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cells. European Journal of Endocrinology, 2002, 147, 269-273.	3.7	67
86	Interleukin-4 and Interleukin-13 Stimulate the Osteoclast Inhibitor Osteoprotegerin by Human Endothelial Cells Through the STAT6 Pathway. Journal of Bone and Mineral Research, 2008, 23, 750-758.	2.8	67
87	Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica, 2013, 98, 1677-1685.	3.5	67
88	Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. European Journal of Endocrinology, 1998, 139, 152-154.	3.7	66
89	Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochemical and Biophysical Research Communications, 2005, 338, 687-693.	2.1	66
90	Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death and Disease, 2019, 10, 91.	6.3	66

#	Article	IF	Citations
91	Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cellsin Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 6139-6145.	3.6	65
92	Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis, 2006, 184, 446-447.	0.8	65
93	High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer, 2014, 14, 649.	2.6	65
94	Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. Journal of Cellular Biochemistry, 2005, 96, 1244-1253.	2.6	64
95	The Anti-Androgen Hydroxyflutamide and Androgens Inhibit Interleukin-6 Production by an Androgen-Responsive Human Osteoblastic Cell Line. Journal of Bone and Mineral Research, 1999, 14, 1330-1337.	2.8	63
96	Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. European Journal of Endocrinology, 2009, 161, 27-35.	3.7	63
97	The German ACROSTUDY: past and present. European Journal of Endocrinology, 2009, 161, S3-S10.	3.7	62
98	Effects of Parathyroid Hormone on Bone Mass, Bone Strength, and Bone Regeneration in Male Rats With Type 2 Diabetes Mellitus. Endocrinology, 2014, 155, 1197-1206.	2.8	62
99	Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Alimentary Pharmacology and Therapeutics, 2003, 17, 807-816.	3.7	60
100	The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leukemia Research, 2012, 36, 525-536.	0.8	60
101	Endocrine Implications of Human Immunodeficiency Virus Infection. Medicine (United States), 1996, 75, 262-278.	1.0	59
102	Sulfated Glycosaminoglycans Support Osteoblast Functions and Concurrently Suppress Osteoclasts. Journal of Cellular Biochemistry, 2014, 115, 1101-1111.	2.6	59
103	Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling. Nature Metabolism, 2019, 1, 111-124.	11.9	59
104	Inhibition of Lamin A/C Attenuates Osteoblast Differentiation and Enhances RANKL-Dependent Osteoclastogenesis. Journal of Bone and Mineral Research, 2009, 24, 78-86.	2.8	58
105	Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Letters, 2010, 287, 109-116.	7.2	57
106	Increased EPO Levels Are Associated With Bone Loss in Mice Lacking PHD2 in EPO-Producing Cells. Journal of Bone and Mineral Research, 2016, 31, 1877-1887.	2.8	56
107	Immune Suppressive and Bone Inhibitory Effects of Prednisolone in Growing and Regenerating Zebrafish Tissues. Journal of Bone and Mineral Research, 2017, 32, 2476-2488.	2.8	56
108	Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. Biomaterials, 2016, 96, 11-23.	11.4	55

#	Article	IF	Citations
109	VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 2002, 132, 1056-1063.	1.9	53
110	Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. Endocrinology, 2015, 156, 3517-3527.	2.8	53
111	Soluble Interleukin-1 Receptor Antagonist Serum Levels in Smokers and Nonsmokers with Graves' Ophthalmopathy Undergoing Orbital Radiotherapy. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2244-2247.	3.6	53
112	Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology, 2006, 45, 1218-1222.	1.9	52
113	Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. Journal of Cellular Biochemistry, 1998, 71, 96-108.	2.6	51
114	Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men. Circulation, 2003, 107, e76; author reply e76.	1.6	51
115	Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clinical Endocrinology, 2004, 60, 214-219.	2.4	49
116	Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. Diabetologia, 2011, 54, 2690-2701.	6.3	49
117	Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. Journal of Cellular Biochemistry, 2011, 112, 1593-1600.	2.6	49
118	Dissociation of Osteogenic and Immunological Effects by the Selective Glucocorticoid Receptor Agonist, Compound A, in Human Bone Marrow Stromal Cells. Endocrinology, 2011, 152, 103-112.	2.8	48
119	Correlates of bone microarchitectural parameters and serum sclerostin levels in men: The STRAMBO study. Journal of Bone and Mineral Research, 2013, 28, 1760-1770.	2.8	47
120	Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clinical Endocrinology, 2014, 80, 649-655.	2.4	47
121	Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. Bone, 2016, 82, 108-115.	2.9	46
122	Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. European Journal of Gastroenterology and Hepatology, 2003, 15, 1165-1170.	1.6	45
123	Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors. Haematologica, 2016, 101, 1499-1507.	3.5	45
124	Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Molecular and Cellular Endocrinology, 2007, 264, 74-81.	3.2	44
125	Endocrine and Clinical Correlates of Myostatin Serum Concentration in Menâ€"the STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3700-3708.	3.6	44
126	Denosumab for Post-Transplantation Hypercalcemia in Osteopetrosis. New England Journal of Medicine, 2012, 367, 1766-1767.	27.0	43

#	Article	IF	Citations
127	Osteoprotegerin: A new biomarker for impaired bone metabolism in complex regional pain syndrome?. Pain, 2014, 155, 889-895.	4.2	43
128	Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer. Annals of Surgical Oncology, 2014, 21, 1891-1897.	1.5	43
129	The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. European Journal of Endocrinology, 2014, 171, 727-735.	3.7	43
130	p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death and Disease, 2016, 7, e2119-e2119.	6.3	43
131	Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia, 2007, 50, 1243-1247.	6.3	42
132	WNT5A Has Anti-Prostate Cancer Effects In Vitro and Reduces Tumor Growth in the Skeleton In Vivo. Journal of Bone and Mineral Research, 2015, 30, 471-480.	2.8	42
133	Bioinspired Collagen/Glycosaminoglycan-Based Cellular Microenvironments for Tuning Osteoclastogenesis. ACS Applied Materials & Interfaces, 2015, 7, 23787-23797.	8.0	42
134	Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone, 2009, 45, 677-681.	2.9	41
135	Effects of the Selective Glucocorticoid Receptor Modulator Compound A on Bone Metabolism and Inflammation in Male Mice With Collagen-Induced Arthritis. Endocrinology, 2013, 154, 3719-3728.	2.8	41
136	Milk Fat Globule-Epidermal Growth Factor 8 (MFG-E8) Is a Novel Anti-inflammatory Factor in Rheumatoid Arthritis in Mice and Humans. Journal of Bone and Mineral Research, 2016, 31, 596-605.	2.8	41
137	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. Bone, 2020, 134, 115268.	2.9	41
138	Emerging Players in Prostate Cancerâ€“Bone Niche Communication. Trends in Cancer, 2021, 7, 112-121.	7.4	41
139	Osteoprotegerin Gene Polymorphism and the Risk of Osteoporosis and Vascular Disease. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4078-4079.	3.6	40
140	Regulation of bone mass and osteoclast function depend on the F-actin modulator SWAP-70. Journal of Bone and Mineral Research, 2012, 27, 2085-2096.	2.8	40
141	GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporosis International, 2016, 27, 2967-2978.	3.1	40
142	Serum measurement of osteoprotegerin--clinical relevance and potential applications. European Journal of Endocrinology, 2001, 145, 681-683.	3.7	39
143	Skeletal and extraskeletal actions of denosumab. Endocrine, 2012, 42, 52-62.	2.3	39
144	Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone. Biomaterials, 2015, 67, 335-345.	11.4	39

#	Article	IF	Citations
145	Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Cancer Letters, 2016, 375, 162-171.	7.2	39
146	Artificial Extracellular Matrices with Oversulfated Glycosaminoglycan Derivatives Promote the Differentiation of Osteoblast-Precursor Cells and Premature Osteoblasts. BioMed Research International, 2014, 2014, 1-10.	1.9	38
147	Postnatal Skeletal Deletion of Dickkopf-1 Increases Bone Formation and Bone Volume in Male and Female Mice, Despite Increased Sclerostin Expression. Journal of Bone and Mineral Research, 2018, 33, 1698-1707.	2.8	38
148	In Vitro and in Vivo Angiogenesis in PC12 Pheochromocytoma Cells is Mediated by Vascular Endothelial Growth Factor. Experimental and Clinical Endocrinology and Diabetes, 2002, 110, 386-392.	1.2	37
149	Osteoprotegerin expression in dendritic cells increases with maturation and is NF-Î¹B-dependent. Journal of Cellular Biochemistry, 2007, 100, 1430-1439.	2.6	37
150	Denosumab for bone diseases: translating bone biology into targeted therapy. European Journal of Endocrinology, 2011, 165, 833-840.	3.7	37
151	Differential effects of high-fat diet and exercise training on bone and energy metabolism. Bone, 2018, 116, 120-134.	2.9	37
152	Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection. Journal of Bone and Mineral Research, 2001, 16, 2-9.	2.8	36
153	Long-Term Cyclic Strain Downregulates Endothelial Nox4. Antioxidants and Redox Signaling, 2009, 11, 2385-2397.	5.4	36
154	A novel resorption assay for osteoclast functionality based on an osteoblastâ€derived native extracellular matrix. Journal of Cellular Biochemistry, 2010, 109, 1025-1032.	2.6	36
155	The Osteoclast-Associated Receptor (OSCAR) Is a Novel Receptor Regulated by Oxidized Low-Density Lipoprotein in Human Endothelial Cells. Endocrinology, 2011, 152, 4915-4926.	2.8	36
156	Ebf factors and MyoD cooperate to regulate muscle relaxation via Atp2a1. Nature Communications, 2014, 5, 3793.	12.8	36
157	Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Letters, 2014, 346, 172-177.	7.2	36
158	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Journal of Cellular Biochemistry, 2002, 86, 642-650.	2.6	35
159	Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: Report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transplant International, 2011, 24, 867-879.	1.6	35
160	An appendix to the 2012 IOFâ€“ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 2012, 7, 25-30.	2.4	35
161	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. American Journal of Medicine, 2013, 126, 174-180.	1.5	35
162	Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. International Journal of Cancer, 2015, 136, 44-54.	5.1	35

#	Article	IF	Citations
163	Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. Scientific Reports, 2016, 5, 18138.	3.3	35
164	Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats. PLoS ONE, 2015, 10, e0131192.	2.5	35
165	Insulin-like growth factor I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine. European Journal of Endocrinology, 1995, 132, 605-610.	3.7	34
166	Fatal attraction: why breast cancer cells home to bone. Breast Cancer Research, 2008, 10, 101.	5.0	34
167	Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAILâ€induced apoptosis. Journal of Cellular Biochemistry, 2009, 108, 106-116.	2.6	34
168	Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo. Scientific Reports, 2018, 8, 8711.	3.3	33
169	Isopropanolic Extract of Black Cohosh Stimulates Osteoprotegerin Production by Human Osteoblasts. Journal of Bone and Mineral Research, 2005, 20, 2036-2043.	2.8	32
170	The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-ÎºB ligand/osteoprotegerin complex formation. Biomaterials, 2013, 34, 7653-7661.	11.4	32
171	Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy. Mayo Clinic Proceedings, 2013, 88, 418-419.	3.0	32
172	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Research, 2014, 16, R20.	5.0	32
173	Increased pore size of scaffolds improves coating efficiency with sulfated hyaluronan and mineralization capacity of osteoblasts. Biomaterials Research, 2019, 23, 26.	6.9	32
174	The Prevalence of Familial Hyperaldosteronism in Apparently Sporadic Primary Aldosteronism in Germany: a Single Center Experience. Hormone and Metabolic Research, 2012, 44, 215-220.	1.5	31
175	Cathepsin S controls adipocytic and osteoblastic differentiation, bone turnover, and bone microarchitecture. Bone, 2014, 64, 281-287.	2.9	31
176	Severe Abdominal Aortic Calcification in Older Men Is Negatively Associated With DKK1 Serum Levels: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 617-624.	3.6	29
177	Expression of receptor activator of NF-?B ligand (RANKL) mRNA in human multiple myeloma cells. Journal of Cancer Research and Clinical Oncology, 2004, 130, 469-74.	2.5	28
178	Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine, 2007, 31, 105-113.	2.3	28
179	Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Experimental Hematology, 2012, 40, 867-876.	0.4	28
180	Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1671-1680.	2.5	28

#	Article	IF	Citations
181	Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. International Journal of Endocrinology, 2015, 2015, 1-9.	1.5	28
182	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clinical Cancer Research, 2019, 25, 1369-1378.	7.0	28
183	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thrombosis and Haemostasis, 2006, 95, 708-714.	3.4	27
184	Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochemical and Biophysical Research Communications, 2011, 407, 103-107.	2.1	27
185	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. Oncotarget, 2018, 9, 27293-27304.	1.8	27
186	Graves Disease Associated With Autoimmune Thrombocytopenic Purpura. Archives of Internal Medicine, 1997, 157, 1033.	3.8	26
187	Seizures Associated with Zoledronic Acid for Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1955-1959.	3.6	26
188	Multiple endocrine neoplasia type 2: recent progress in diagnosis and management. European Journal of Endocrinology, 1997, 137, 572-578.	3.7	25
189	Myelodysplastic syndromes and bone loss in mice and men. Leukemia, 2017, 31, 1003-1007.	7.2	25
190	Osteogenic Dkk1 Mediates Glucocorticoid-Induced but Not Arthritis-Induced Bone Loss. Journal of Bone and Mineral Research, 2019, 34, 1314-1323.	2.8	25
191	Evolving functions of Dickkopf-1 in cancer and immunity. Cancer Letters, 2020, 482, 1-7.	7.2	25
192	Skeletal Effects of Cyclosporin A Are Gender Related in Rats. Endocrinology, 2003, 144, 40-49.	2.8	24
193	17Î²-Estradiol inhibits osteoprotegerin production by the estrogen receptor-Î±-positive human breast cancer cell line MCF-7. Biochemical and Biophysical Research Communications, 2008, 368, 736-741.	2.1	24
194	Disruption of a Nuclear NFATc2 Protein Stabilization Loop Confers Breast and Pancreatic Cancer Growth Suppression by Zoledronic Acid. Journal of Biological Chemistry, 2011, 286, 28761-28771.	3.4	24
195	Novel therapies in benign and malignant bone diseases. , 2012, 134, 338-344.		24
196	Development and characterization of a conditionally immortalized human osteoblastic cell line stably transfected with the human androgen receptor gene. , 1997, 66, 542-551.		23
197	Cortical Bone Status Is Associated with Serum Osteoprotegerin Concentration in Men: The STRAMBO Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2216-2226.	3.6	23
198	Associations between ambient air pollution and bone turnover markers in 10-year old children: Results from the GINIplus and LISAplus studies. International Journal of Hygiene and Environmental Health, 2015, 218, 58-65.	4.3	23

#	Article	IF	Citations
199	KrÃ¼ppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells. Bone, 2012, 50, 723-732.	2.9	22
200	The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporosis International, 2014, 25, 339-347.	3.1	22
201	Neuropilinâ€2 is an independent prognostic factor for shorter cancerâ€specific survival in patients with acinar adenocarcinoma of the prostate. International Journal of Cancer, 2020, 146, 2619-2627.	5.1	22
202	The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. Frontiers in Cell and Developmental Biology, 2020, 8, 586031.	3.7	22
203	The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS ONE, 2016, 11, e0155087.	2.5	21
204	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. Breast Cancer Research, 2017, 19, 92.	5.0	21
205	Bad to the Bone: The Effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Frontiers in Endocrinology, 2022, 13, 835720.	3.5	21
206	TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. Biochemical and Biophysical Research Communications, 2005, 338, 1745-1750.	2.1	20
207	Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. Bone, 2014, 67, 175-180.	2.9	20
208	Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. Breast Cancer Research and Treatment, 2015, 154, 623-631.	2.5	20
209	Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism. Endocrinology, 2017, 158, 3765-3777.	2.8	20
210	Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2233-2238.	2.5	20
211	The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. International Journal of Molecular Sciences, 2021, 22, 5078.	4.1	20
212	Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line. Endocrinology, 1999, 140, 5579-5586.	2.8	20
213	Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. Haematologica, 2011, 96, 1580-1588.	3.5	19
214	Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. Experimental Hematology, 2012, 40, 934-944.	0.4	19
215	Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED) â€“ A prospective multicenter study. Epilepsy Research, 2013, 106, 417-422.	1.6	19
216	Loss of milk fat globule-epidermal growth factor 8 (MFG-E8) in mice leads to low bone mass and accelerates ovariectomy-associated bone loss by increasing osteoclastogenesis. Bone, 2015, 76, 107-114.	2.9	19

#	Article	IF	Citations
217	Bone Formation and the Wnt Signaling Pathway. New England Journal of Medicine, 2016, 375, 1902-1903.	27.0	19
218	Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. Bone, 2019, 120, 44-49.	2.9	19
219	Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. Journal of Steroid Biochemistry and Molecular Biology, 2020, 204, 105734.	2.5	19
220	Thyroid Hormone Actions and Bone Remodeling â€“ The Role of the Wnt Signaling Pathway. Experimental and Clinical Endocrinology and Diabetes, 2020, 128, 450-454.	1.2	19
221	Intercellular chatter: osteoblasts, osteoclasts and interleukin 6. European Journal of Endocrinology, 1996, 134, 425-426.	3.7	17
222	Microdialysis Sampling from Wound Fluids Enables Quantitative Assessment of Cytokines, Proteins, and Metabolites Reveals Bone Defect-Specific Molecular Profiles. PLoS ONE, 2016, 11, e0159580.	2.5	17
223	Loss of Dkk-1 in Osteocytes Mitigates Alveolar Bone Loss in Mice With Periodontitis. Frontiers in Immunology, 2019, 10, 2924.	4.8	17
224	Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. Bone Research, 2021, 9, 24.	11.4	17
225	Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight, 2020, 5, .	5.0	17
226	Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. Acta Neuropathologica, 2004, 107, 575-577.	7.7	16
227	Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Molecular Cancer, 2014, 13, 265.	19.2	16
228	Zoledronic acid and atorvastatin inhibit Î±vÎ²3-mediated adhesion of breast cancer cells. Journal of Bone Oncology, 2014, 3, 10-17.	2.4	16
229	Serum fetuin-A levels and abdominal aortic calcification in healthy men â€” The STRAMBO study. Bone, 2015, 79, 196-202.	2.9	16
230	Exosomal miRNAs from Prostate Cancer Impair Osteoblast Function in Mice. International Journal of Molecular Sciences, 2022, 23, 1285.	4.1	16
231	Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial. American Journal of Clinical Nutrition, 2022, 115, 1311-1321.	4.7	16
232	Osteopetrosis in cathepsin K-deficient mice. European Journal of Endocrinology, 1999, 140, 376-377.	3.7	15
233	Serum myostatin levels are negatively associated with abdominal aortic calcification in older men: the STRAMBO study. European Journal of Endocrinology, 2012, 167, 873-880.	3.7	15
234	Quantitative proteomics reveals novel functions of osteoclast-associated receptor in STAT signaling and cell adhesion in human endothelial cells. Journal of Molecular and Cellular Cardiology, 2012, 53, 829-837.	1.9	15

#	Article	IF	Citations
235	High serum levels of periostin are associated with a poor survival in breast cancer. Breast Cancer Research and Treatment, 2020, 180, 515-524.	2.5	15
236	Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells. Leukemia, 2021, 35, 2936-2947.	7.2	15
237	Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans. Endocrine Connections, 2019, 8, 923-934.	1.9	15
238	Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thrombosis and Haemostasis, 2006, 95, 708-14.	3.4	15
239	Functional Thyrotropin Receptor Attenuates Malignant Phenotype of Follicular Thyroid Cancer Cells. Endocrine, 2006, 30, 129-138.	2.2	14
240	More DATA to guide sequential osteoporosis therapy. Lancet, The, 2015, 386, 1116-1118.	13.7	14
241	Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway. Haematologica, 2018, 103, 61-68.	3.5	14
242	Epo/EpoR signaling in osteoprogenitor cells is essential for bone homeostasis and Epo-induced bone loss. Bone Research, 2021, 9, 42.	11.4	14
243	Endocrinology meets immunology: T lymphocytes as novel targets for melatonin. European Journal of Endocrinology, 1996, 134, 424-425.	3.7	13
244	Gorhamâ€“Stout disease (phantom bone) of the shoulder girdle. Rheumatology, 1999, 38, 904-905.	1.9	13
245	The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer Letters, 2011, 312, 101-108.	7.2	13
246	Combined Use of 68Ga-DOTATATE and 18F-FDG PET/CT to Localize a Bronchial Carcinoid Associated with Ectopic ACTH Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2207-2208.	3.6	13
247	Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells. Stem Cells, 2016, 34, 2224-2235.	3.2	13
248	WNT5A and Its Receptors in the Bone-Cancer Dialogue. Journal of Bone and Mineral Research, 2016, 31, 1488-1496.	2.8	13
249	Effects of parathyroid hormone on cortical porosity, non-enzymatic glycation and bone tissue mechanics in rats with type 2 diabetes mellitus. Bone, 2016, 82, 116-121.	2.9	13
250	Thyrotropin serum levels are differentially associated with biochemical markers of bone turnover and stiffness in women and men: results from the SHIP cohorts. Osteoporosis International, 2016, 27, 719-727.	3.1	13
251	Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report. Diabetes Care, 2018, 41, e23-e24.	8.6	13
252	Thy-1 Deficiency Augments Bone Loss in Obesity by Affecting Bone Formation and Resorption. Frontiers in Cell and Developmental Biology, 2018, 6, 127.	3.7	13

#	Article	IF	Citations
253	Disruption of <scp>BMP</scp> Signaling Prevents Hyperthyroidismâ€Induced Bone Loss in Male Mice. Journal of Bone and Mineral Research, 2020, 35, 2058-2069.	2.8	13
254	Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-Î°B ligand (RANKL) in heterotopic vascular ossification. Thrombosis and Haemostasis, 2005, 94, 1335-1337.	3.4	12
255	Paneling human thyroid cancer cell lines for candidate proteins for targeted anti-angiogenic therapy. Journal of Cellular Biochemistry, 2006, 98, 954-965.	2.6	12
256	From bone to breast and back - the bone cytokine RANKL and breast cancer. Breast Cancer Research, 2011, 13, 107.	5.0	12
257	Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions. Clinical Biochemistry, 2012, 45, 237-242.	1.9	12
258	Monocytic expression of osteoclast-associated receptor (OSCAR) is induced in atherosclerotic mice and regulated by oxidized low-density lipoprotein in vitro. Biochemical and Biophysical Research Communications, 2013, 437, 314-318.	2.1	12
259	Monitoring of the first stages of bone healing with microdialysis. Monthly Notices of the Royal Astronomical Society: Letters, 2013, 84, 76-81.	3.3	12
260	The Role of Dickkopf-1 in Thyroid Hormoneâ€“Induced Changes of Bone Remodeling in Male Mice. Endocrinology, 2019, 160, 664-674.	2.8	12
261	Role of osteogenic Dickkopf-1 in bone remodeling and bone healing in mice with type I diabetes mellitus. Scientific Reports, 2021, 11, 1920.	3.3	12
262	New insights into the role of glycosaminoglycans in the endosteal bone microenvironment. Biological Chemistry, 2021, 402, 1415-1425.	2.5	12
263	Shaping the bone through iron and iron-related proteins. Seminars in Hematology, 2021, 58, 188-200.	3.4	12
264	Familial severe congenital neutropenia associated with infantile osteoporosis: A new entity. American Journal of Hematology, 2003, 72, 34-37.	4.1	11
265	Glycosaminoglycans and their sulfate derivatives differentially regulate the viability and gene expression of osteocyte-like cell lines. Journal of Bioactive and Compatible Polymers, 2014, 29, 474-485.	2.1	11
266	P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2015, 466, 728-732.	2.1	11
267	Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. Bone, 2020, 137, 115400.	2.9	11
268	Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2885-e2894.	3.6	11
269	Mice lacking DKK1 in TÂcells exhibit high bone mass and are protected from estrogen-deficiency-induced bone loss. IScience, 2021, 24, 102224.	4.1	11
270	Osteometabolic and Osteogenetic Pattern of Turkish Immigrants in Germany. Experimental and Clinical Endocrinology and Diabetes, 2012, 120, 517-523.	1.2	10

#	Article	IF	Citations
271	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. Journal of Bone Oncology, 2013, 2, 110-115.	2.4	10
272	Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes. Annals of Hematology, 2019, 98, 2063-2072.	1.8	10
273	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3122-3133.	3.6	10
274	Contributions of Dickkopfâ€1 to Obesityâ€Induced Bone Loss and Marrow Adiposity. JBMR Plus, 2020, 4, e10364.	2.7	10
275	Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. Journal of Bone Oncology, 2014, 3, 18-24.	2.4	9
276	Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven. Bone, 2015, 75, 183-191.	2.9	9
277	Sweet and brittle â€" Diabetes mellitus and the skeleton. Bone, 2016, 82, 1.	2.9	9
278	Associations of myeloid hematological diseases of the elderly with osteoporosis: A longitudinal analysis of routine health care data. Leukemia Research, 2018, 69, 81-86.	0.8	9
279	Lack of the Thyroid Hormone Transporter Mct8 in Osteoblast and Osteoclast Progenitors Increases Trabecular Bone in Male Mice. Thyroid, 2020, 30, 329-342.	4.5	9
280	From Pharmacology to Physiology: Endocrine Functions of Î¼-Opioid Receptor Networks. Trends in Endocrinology and Metabolism, 2021, 32, 306-319.	7.1	9
281	Graves disease associated with autoimmune thrombocytopenic purpura. Archives of Internal Medicine, 1997, 157, 1033-1036.	3.8	9
282	Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications. Current Pharmaceutical Design, 2016, 22, 2323-2332.	1.9	9
283	Osteoprotegerin: a novel local player in bone metabolism. European Journal of Endocrinology, 1997, 137, 345-346.	3.7	8
284	Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients. Breast Cancer Research and Treatment, 2017, 164, 737-743.	2.5	8
285	Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. Oncogene, 2019, 38, 4773-4787.	5.9	8
286	Skeletal endocrinology: where evolutionary advantage meets disease. Bone Research, 2021, 9, 28.	11.4	8
287	Dermatitis Herpetiformis Cured by Hormone Replacement for Panhypopituitarism.. Endocrine Journal, 1997, 44, 437-440.	1.6	7
288	Multimodal Therapy for Vertebral Involvement of Systemic Mastocytosis. Spine, 2009, 34, E626-E628.	2.0	7

#	Article	IF	Citations
289	Calcification inhibitors in vascular calciphylaxis associated with normal renal function. Thrombosis and Haemostasis, 2012, 108, 1241-1243.	3.4	7
290	Effects of adolescence-onset hypogonadism on metabolism, bone mineral density and quality of life in adulthood. Journal of Pediatric Endocrinology and Metabolism, 2015, 28, 1047-55.	0.9	7
291	Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. Journal of Bone and Mineral Research, 2017, 32, 2288-2296.	2.8	7
292	Interactions of Anemia, FGF-23, and Bone in Healthy Adultsâ€"Results From the Study of Health in Pomerania (SHIP). Journal of Clinical Endocrinology and Metabolism, 2021, 106, e288-e299.	3.6	7
293	Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations. Ageing Research Reviews, 2021, 67, 101301.	10.9	7
294	Basics of Bone Biology. , 2012, , 1-26.		7
295	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. Endocrine, 2011, 40, 75-79.	2.3	6
296	Are there still east-to-west differences in the incidence of hip fractures in Germany?. Archives of Osteoporosis, 2014, 9, 195.	2.4	6
297	Macroglossia as the only presenting feature of amyloidosis due to MGUS. European Journal of Haematology, 2014, 92, 88-89.	2.2	6
298	Sclerostin Blockadeâ€"A Dual Mode of Action After All?. Journal of Bone and Mineral Research, 2016, 31, 1787-1790.	2.8	6
299	Site-Specific Variations in Bone Mineral Density under Systemic Conditions Inducing Osteoporosis in Minipigs. Frontiers in Physiology, 2017, 8, 426.	2.8	6
300	Selective inhibition of receptor activator of NF-ÎºB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction. Journal of Molecular Medicine, 2018, 96, 559-573.	3.9	6
301	Greetings from below the aortic arch! The paradigm of cardiac paraganglioma. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 891-895.	3.6	6
302	Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene, 2022, 41, 3747-3760.	5.9	6
303	Human immunodeficiency virus infection and the thyroid gland. European Journal of Endocrinology, 1996, 134, NP-674.	3.7	5
304	Mediastinal parathyroid tumor: Giant adenoma or carcinoma?. Endocrine Pathology, 1997, 8, 161-166.	9.0	5
305	Skeletal and Soft Tissue Involvement in Mazabraud Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1381-E1382.	3.6	5
306	Effects of insulin therapy on porosity, non-enzymatic glycation and mechanical competence in the bone of rats with type 2 diabetes mellitus. Bone, 2016, 91, 186-193.	2.9	5

#	Article	IF	Citations
307	Systemic PPARÎ³ Antagonism Reduces Metastatic Tumor Progression in Adipocyte-Rich Bone in Excess Weight Male Rodents. Journal of Bone and Mineral Research, 2020, 36, 2440-2452.	2.8	5
308	Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2020, 524, 360-365.	2.1	5
309	Role of milk fat globule-epidermal growth factor 8 in osteoimmunology. BoneKEy Reports, 2016, 5, 820.	2.7	5
310	The mevalonate pathway in breast cancer biology. Cancer Letters, 2022, 542, 215761.	7.2	5
311	Updating the metalloprotease nomenclature: bone morphogenetic protein 1 identified as procollagen C proteinase. European Journal of Endocrinology, 1996, 135, 35-36.	3.7	4
312	Denosumab: a new treatment option for glucocorticoid-induced osteoporosis. Lancet Diabetes and Endocrinology,the, 2018, 6, 428-429.	11.4	4
313	Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. Journal of Bone and Mineral Research, 2009, 24, 090212105514065-34.	2.8	4
314	Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients. Clinical Chemistry and Laboratory Medicine, 2022, 60, 109-117.	2.3	4
315	The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice. Endocrinology, 2022, 163, .	2.8	4
316	Vitamin D receptor knock-out mice: the expectational and the exceptional. European Journal of Endocrinology, 1998, 138, 372-373.	3.7	3
317	From Bone Cell Biology to Novel Therapies of Osteoporosis. Drug Research, 2015, 65, S14-S15.	1.7	3
318	Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks. Cells, 2020, 9, 2443.	4.1	3
319	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. Journal of Bone and Mineral Research, 2020, 36, 1906-1913.	2.8	3
320	Impact Of The Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib In Young Rats On The Vertebral Body. Blood, 2013, 122, 1472-1472.	1.4	3
321	Bone cell-specific deletion of thyroid hormone transporter Mct8 distinctly regulates bone volume in young versus adult male mice. Bone, 2022, 159, 116375.	2.9	3
322	Taking the message to the nucleus: MAD protein as a mediator of bone morphogenetic protein signaling. European Journal of Endocrinology, 1996, 135, 654-655.	3.7	2
323	Identical twins with hypercalcaemia due to Lowe's syndrome. Rheumatology, 2001, 40, 107-108.	1.9	2
324	Optimizing management of myelodysplastic syndromes post-allogeneic transplantation. Expert Review of Hematology, 2011, 4, 669-680.	2.2	2

#	Article	IF	Citations
325	Pulmonary Metastases due to a Giant-Cell Tumor of Bone. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3408-3409.	3.6	2
326	Cancer-targeted therapies and radiopharmaceuticals. BoneKEy Reports, 2015, 4, 707.	2.7	2
327	Prospects of adjuvant RANKL inhibition in breast cancer?. Cell Death and Disease, 2015, 6, e1982-e1982.	6.3	2
328	Rodent Models of Spondyloarthritis Have Decreased White and Bone Marrow Adipose Tissue Depots. Frontiers in Immunology, 2021, 12, 665208.	4.8	2
329	Dehydroepiandrosterone Supplementation in Elderly Men: The Role of Estrogens Versus Androgens on the Male Skeleton. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4009-4009.	3.6	2
330	Viscous hearing loss. Lancet, The, 1995, 345, 1243.	13.7	1
331	How iodide gets access to thyrocytes: molecular details on the thyroid iodide transporter. European Journal of Endocrinology, 1996, 135, 34-35.	3.7	1
332	Antibodies targeting the calcium sensing receptor: acquired hypoparathyroidismâ€"an autoimmune disease at last?. European Journal of Endocrinology, 1996, 135, 172-173.	3.7	1
333	Hyperactive channels and inherited hypertension: Liddle's syndrome â€“ an epithelial sodium channelopathy. European Journal of Endocrinology, 1997, 136, 588-589.	3.7	1
334	Less can be more â€“ at least in mice: osteocalcin deficiency associated with increased bone formation. European Journal of Endocrinology, 1997, 136, 586-587.	3.7	1
335	Deconstructing Vitamin D Deficiency. Science Translational Medicine, 2013, 5, 193fs27.	12.4	1
336	Pharmacological mechanisms of therapeutics. , 2020, , 1689-1710.		1
337	High stromaâ€derived WNT5A is an indicator for lowâ€risk prostate cancer. FEBS Open Bio, 2021, 11, 1186-1194.	2.3	1
338	Effects of gonadal and adrenal androgens in a novel androgenâ€responsive human osteoblastic cell line. Journal of Cellular Biochemistry, 1998, 71, 96-108.	2.6	1
339	Skeletal Effects of the Tyrosine Kinase Inhibitors Imatinib, Dasatinib, and Bosutinib in Young Rats. Blood, 2012, 120, 4429-4429.	1.4	1
340	Bone Metabolism in Cancer. , 2020, , 503-511.		1
341	Skeletal health in patients following allogeneic hematopoietic cell transplantation. Bone, 2020, , 115684.	2.9	1
342	Effect of Anti-Osteoporotic Treatments on Circulating and Bone MicroRNA Patterns in Osteopenic ZDF Rats. International Journal of Molecular Sciences, 2022, 23, 6534.	4.1	1

#	Article	IF	Citations
343	Environmental endocrinology: Hidden, but potent ways of activating the estrogen receptor. European Journal of Endocrinology, 1996, 135, 653-654.	3.7	0
344	Of bone and genes: vitamin D receptor polymorphism and primary hyperparathyroidism. European Journal of Endocrinology, 1996, 134, 685-686.	3.7	0
345	Cytokine inhibition: a new therapeutic avenue for skeletal diseases. Drug Discovery Today, 2002, 7, 289.	6.4	0
346	Nox4 Controls Bone Mass by Regulation of Osteoclastogenisis. Free Radical Biology and Medicine, 2011, 51, S97.	2.9	0
347	Denosumab for bone diseases: translating bone biology into targeted therapy. European Journal of Endocrinology, 2012, 166, 137.	3.7	0
348	Antibodies for the Treatment of Bone Diseases: Clinical Data. , 2016, , 239-255.		0
349	A Novel Strategy for Repairing Multiple Myeloma Bone Lesions: Lessons From Murine Models. Journal of Bone and Mineral Research, 2019, 34, 781-782.	2.8	0
350	Leopard skin. Lancet Diabetes and Endocrinology,the, 2020, 8, 456.	11.4	0
351	Diabetes Mellitus and Osteoporosis. , 2011, , 103-108.		0
352	RANKL Inhibition: Clinical Data. , 2012, , 217-240.		0
353	The novel selective glucocorticoid receptor modulator compound A maintains osteoblast function and the RANKL/OPG ratio in mice. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, .	1.2	0
354	Interaktion von Tumorzellen und Knochen bei osteolytischen/osteosklerotischen Metastasen, Circulus vitiosus der Knochenmetastasierung. , 2014, , 13-21.		0
355	Glycosaminoglycans and their sulfate derivatives differentially regulate the vitality and gene expression of osteocyte-like cell lines. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
356	Sclerostin is a target of glucocorticoid therapy in vitro and in vivo. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
357	Improvement of osteoblast function and effect of intermittent PTH therapy in high glucose conditions via blocking of N-linked glycosylation. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
358	Basics of Bone Biology. , 2016, , 1-30.		0
359	Bedeutung von RANK-Ligand und Osteoprotegerin fÃ¼r den Knochenstoffwechsel. , 2006, , 479-509.		0
360	Osteoonkologie: Von der Biologie zu neuen Therapien. , 0, , .		0

#	Article	IF	Citations
361	Knochenmetastasen: Stellenwert von Biomarkern bei der FrÃ¼hdiagnose. , 0, , .		0